Lipella Pharmaceuticals Inc (LIPO) Return on Assets ROA from the third quarter of 2025 to third quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
Lipella Pharmaceuticals Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Lipella Pharmaceuticals Inc 's ROA in the third quarter of 2025?
Lipella Pharmaceuticals Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -156.76%.
However, within the Healthcare sector 836 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4530, from total ROA ranking in the second quarter of 2025 at 4618.
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference Lipella Pharmaceuticals Inc., a leading innovator in urological health, has announced a breakthrough in bladder imaging technology at the International Conference on Innovations in Clinical Journeys (ICICJ). This new technique is poised to revolutionize the way bladder conditions are diagnosed and managed, offering unprecedented clarity and detail in imaging results.At the ICICJ Conference, held this week in New York, Lipella s team of scientists and researchers demonstrated the novel imaging method, which utilizes a combination of advanced optical and digital enhancements to produce high-resolution images of the bladder. This technology promises to improve diagnostic accuracy, enabling healthcare professionals to detect and monitor bladder conditions with greater precision and efficiency.
Pittsburgh, PA October 2023 Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has successfully dosed the first two patients in its eagerly anticipated Phase 2a clinical trial for the treatment of Oral Lichen Planus (OLP). This significant milestone marks a major step forward in the company s mission to develop effective treatments for this chronic inflammatory condition, which affects the mucous membranes of the mouth and can cause considerable pain and discomfort.Oral Lichen Planus, though not life-threatening, presents a persistent and challenging array of symptoms, including painful sores, burning sensations, and ulcerations in the oral cavity. Current treatments primarily focus on symptom management, often not providing comprehensive relief or addressing the underlying causes of the condition. Lipella Pharmaceuticals innovative approach leverages its proprietary, locally-acting therapeutic technology to target the inflammation and immune responses directly implicated in OLP. By administering the treatment directly to the affected areas within the mouth, the company aims to achieve higher effectiveness with potentially fewer systemic side effects compared to conventional therapies.
In a recent press release, Lipella Pharmaceuticals announced the Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) for LP-410, a potential breakthrough treatment for oral Graft-Versus-Host Disease (GVHD). This exciting development signifies another step forward in Lipella s clinical pipeline, offering hope for patients suffering from this complex condition. GVHD is a common and potentially life-threatening complication that can occur after a stem cell or bone marrow transplant. The condition arises when the newly transplanted immune cells recognize the recipient s body as foreign and attack healthy tissues, particularly affecting the mouth and throat. Oral GVHD can cause severe pain, difficulty eating, and increased susceptibility to infections.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
